MA47408A - CANCER TREATMENT - Google Patents

CANCER TREATMENT

Info

Publication number
MA47408A
MA47408A MA047408A MA47408A MA47408A MA 47408 A MA47408 A MA 47408A MA 047408 A MA047408 A MA 047408A MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A
Authority
MA
Morocco
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
MA047408A
Other languages
French (fr)
Other versions
MA47408B1 (en
Inventor
Anjali Narayan Avadhani
Porre Peter Marie Z De
Yohann Loriot
Ruixo Juan Jose Perez
Arlene O Siefker-Radtke
Kim Stuyckens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47408A publication Critical patent/MA47408A/en
Publication of MA47408B1 publication Critical patent/MA47408B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
MA47408A 2017-12-20 2018-02-02 CANCER TREATMENT MA47408B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (2)

Publication Number Publication Date
MA47408A true MA47408A (en) 2019-12-11
MA47408B1 MA47408B1 (en) 2023-08-31

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47408A MA47408B1 (en) 2017-12-20 2018-02-02 CANCER TREATMENT

Country Status (5)

Country Link
EA (1) EA201991818A1 (en)
MA (1) MA47408B1 (en)
PT (1) PT3576740T (en)
TW (1) TWI798199B (en)
WO (1) WO2018141921A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020058432A1 (en) * 2018-09-21 2020-03-26 Janssen Pharmaceutica Nv Treatment of cholangiocarcinoma
WO2020131674A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020165181A1 (en) * 2019-02-12 2020-08-20 Janssen Pharmaceutica Nv Cancer treatment
US20220202703A1 (en) * 2019-03-15 2022-06-30 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
CA3130773A1 (en) * 2019-03-29 2020-10-08 Peter Marie Z. De Porre Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
SG11202112932QA (en) * 2019-05-31 2021-12-30 Qed Therapeutics Inc Methods of treating urinary system cancers
US20230011935A1 (en) * 2019-12-09 2023-01-12 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
WO2021160764A1 (en) * 2020-02-12 2021-08-19 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (en) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Also Published As

Publication number Publication date
PT3576740T (en) 2023-08-18
EA201991818A1 (en) 2020-02-05
TWI798199B (en) 2023-04-11
TW201839399A (en) 2018-11-01
MA47408B1 (en) 2023-08-31
WO2018141921A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
MA50056A (en) TUMOR TREATMENT PROCESSES
MA47501A (en) CYCLIC DI-NUCLEOTID DERIVATIVE FOR CANCER TREATMENT
MA49144A (en) POLYTHERAPIES FOR THE TREATMENT OF CANCER
MA45192A (en) ASSOCIATION TREATMENT
DK3506854T3 (en) BREAST TREATMENT DEVICE
MA47095A (en) PALAIS MOU TREATMENT
MA45563A (en) OVARIAN CANCER TREATMENT METHODS
MA41449A (en) POLYTHERAPIES FOR THE TREATMENT OF CANCERS
MA47408A (en) CANCER TREATMENT
MA45429A (en) POLYTHERAPY FOR CANCER TREATMENT
MA48637A (en) POLYTHERAPIES FOR THE TREATMENT OF CANCER
MA46361A (en) TREATMENT OF PROSTATE CANCER
MA50409A (en) POLYTHERAPIES FOR THE TREATMENT OF CANCER
DK3474802T3 (en) Medical dressing
MA41555A (en) POLYTHERAPY FOR CANCER TREATMENT
DK3458052T3 (en) Combination treatment of cancer
MA44612A (en) PEDIATRIC CANCER TREATMENT METHODS
MA41123A (en) POLYTHERAPY FOR CANCER TREATMENT
MA45129A (en) CANCER TREATMENTS
MA52627A (en) CANCER TREATMENT
MA49059A (en) TREATMENT OF POSITIVE HER2 CANCERS
MA45780A (en) TREATMENT METHODS FOR PROSTATE CANCER
KR102377742B1 (en) cancer treatment
MA42999A (en) POLYTHERAPY FOR THE TREATMENT OF MALIGNITIES
MA45675A (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER